Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes.

This difference was not statistically significant (HR 0.83, 95% CI 0.52–1.34), likely due to small numbers, but draws some parallels to the PD-L1 CPS ≥10 analysis in KEYNOTE-062 also reporting a nonsignificant trend in favor of adding pembrolizumab to first-line chemotherapy.

also in 5,406 other papers